Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 5350 (107th)

Prescription Affordability and Medicine Safety Act of 2002

referredUnited States· United States Congress· EN

Introduced

9 September 2002

Last action

23 September 2002 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Kennedy, Patrick J. [D-RI-1], Rep. Hilliard, Earl F. [D-AL-7], Rep. Lipinski, William O. [D-IL-3], Rep. Frost, Martin [D-TX-24], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Crowley, Joseph [D-NY-14], Rep. Allen, Thomas H. [D-ME-1], Sen. Sanders, Bernard [I-VT]

Subjects

Healthcare, Taxation, Education

Source updated

19 August 2025

Healthcare · Taxation · Education

Summary

Prescription Affordability and Medicine Safety Act of 2002 - Authorizes appropriations for the Food and Drug Administration (FDA) for generic drug application review and the continuation of the education program on the use and therapeutic equivalency of drugs. Amends the Public Health Service Act to authorize the Secretary of Health and Human Services to make grants to States in support of State pharmacy benefit assistance programs. Requires a percentage of profits from the sale of certain drugs and biological products to be placed in a revolving fund and used to support the grants program. Limits the tax deductions for advertizing for prescription drug manufacturers. Limits the extension of the 30 month stay of FDA approval for any new (generic) drug, as specified, thereby limiting the brand name drug's patent owner's period of exclusive sales. Makes a patent owner's failure to timely file a civil action for infringement a bar to later action. Sets forth requirements for filing drug patent information with the FDA. Makes a patent owner's failure to timely file with the FDA a bar to civil actions for patent infringement. Requires the first generic drug applicant with a specified certification to forfeit the 180 day marketing exclusivity period to a subsequent generic drug applicant if the first generic drug applicant engages in certain behaviors which delay or prevent the marketing of the generic drug.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 9 September 2002

    Introduced

    Introduced in House

    Source: IntroReferral

  2. 9 September 2002

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 9 September 2002

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  4. 9 September 2002

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 23 September 2002

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 9 September 2002

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 9 September 2002

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 9 September 2002

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.